A Novel Strategy To Reduce the Immunogenicity of Biological Therapies-Reference-Cited by-同舟云学术

A Novel Strategy To Reduce the Immunogenicity of Biological Therapies

Published:2010-06-02 Issue:1 Volume:185 Page:763-768
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Somerfield Jennifer,Hill-Cawthorne Grant A.,Lin Andrew,Zandi Michael S.,McCarthy Claire,Jones Joanne L.,Willcox Michael,Shaw David,Thompson Sara A. J.,Compston Alastair S.,Hale Geoff,Waldmann Herman,Coles Alasdair J.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference31 articles.

1. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C

2. The antigenicity of insulin: A review

3. Role of Aggregated Human Growth Hormone (hGH) in Development of Antibodies to hGH*

4. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.;Lusher;Haematologica,2000

5. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED]

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adeno-associated virus-vectored delivery of HIV biologics: the promise of a “single-shot” functional cure for HIV infection;Journal of Virus Eradication;2023-03

2. Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics;Journal of Clinical Medicine;2022-10-19

3. Development and characterization of a novel human CD137 agonistic antibody with anti‐tumor activity and a good safety profile in non‐human primates;FEBS Open Bio;2022-10-09

4. HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys;PLOS Pathogens;2022-04-22

5. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study;The Journal of Rheumatology;2021-12-01